Intellia Therapeutics Gears Up for Secondary Offering

By Chris Lange Updated Jan 12, 6:41AM EST · Published Nov 2, 11:25AM EDT

Intellia Therapeutics Gears Up for Secondary Offering — © Thinkstock

Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares take a dip on Thursday after the firm announced the pricing of its secondary offering. Looking at the chart, this seems to be the perfect time for an offering. The stock has run up about 94% in just 2017, excluding Thursday’s move, and now is a great time to capitalize on this.

The company plans to price its 6.25 million shares of its common stock at a public offering price of $24 per share, with an overallotment option for an additional 937,500 shares. At this price, the entire offering is valued up to $172.5 million. The offering is expected to close on November 6.

The underwriters for the offering are Credit Suisse, Jefferies and Leerink Partners.

For some quick background: this is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as CRISPR/Cas9. Management believes that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes or genetic material in the human body with a single treatment course. The firm intends to leverage its leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new class of therapeutic products.

[nativounit]

Intellia intends to use the net proceeds from this offering, together with its existing cash and cash equivalents for research and development and clinical development costs, to support the advancement of its potential product candidates and the expansion of its research and development programs. The remainder will be put toward working capital, capital expenditures and other general corporate purposes.

Shares of Intellia were last seen down about 16.3% at $21.32, with a consensus analyst price target of $27.83 and a 52-week range of $10.83 to $33.34.

[wallst_email_signup]

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics. Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications. A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.